XNAS
TSHA
Market cap483mUSD
May 13, Last price
2.36USD
1D
1.63%
1Q
47.36%
IPO
-90.36%
Name
Taysha Gene Therapies Inc
Chart & Performance
P/E
—
P/S
58.02
EPS
—
Div Yield, %
—
Shrs. gr., 5y
46.56%
Rev. gr., 5y
%
Revenues
8m
-46.07%
Net income
-89m
L-19.96%
CFO
-81m
L+11.24%
Earnings
Aug 11, 2025
Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 8,333 -46.07% | 15,451 517.55% | 2,502 | |||
Cost of revenue | 94,954 | 86,825 | 131,016 | |||
Unusual Expense (Income) | ||||||
NOPBT | (86,621) | (71,374) | (128,514) | |||
NOPBT Margin | ||||||
Operating Taxes | 3,567 | |||||
Tax Rate | ||||||
NOPAT | (86,621) | (71,374) | (132,081) | |||
Net income | (89,298) -19.96% | (111,566) -34.21% | (169,581) -3.35% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 76,780 | 140,790 | 53,244 | |||
BB yield | -17.74% | -68.50% | -53.60% | |||
| Debt | ||||||
Debt current | 1,646 | 1,521 | ||||
Long-term debt | 34,722 | 78,414 | 78,847 | |||
Deferred revenue | (2,355) | |||||
Other long-term liabilities | 45,251 | 1,577 | 4,130 | |||
Net debt | (104,314) | (63,880) | (10,149) | |||
| Cash flow | ||||||
Cash from operating activities | (81,225) | (73,018) | (88,390) | |||
CAPEX | (374) | (3,869) | (24,869) | |||
Cash from investing activities | (363) | (7,352) | (24,930) | |||
Cash from financing activities | 76,684 | 136,393 | 52,097 | |||
FCF | (82,079) | (65,876) | (107,377) | |||
| Balance | ||||||
Cash | 139,036 | 143,940 | 87,880 | |||
Long term investments | 2,637 | |||||
Excess cash | 138,619 | 143,167 | 90,392 | |||
Stockholders' equity | (606,334) | (513,005) | (401,440) | |||
Invested Capital | 740,471 | 650,626 | 464,092 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 250,134 | 116,121 | 43,952 | |||
Price | 1.73 -2.26% | 1.77 -21.68% | 2.26 -80.60% | |||
Market cap | 432,733 110.54% | 205,535 106.92% | 99,332 -77.35% | |||
EV | 328,419 | 141,655 | 89,183 | |||
EBITDA | (85,376) | (70,003) | (127,342) | |||
EV/EBITDA | ||||||
Interest | 102 | 4,998 | 3,798 | |||
Interest/NOPBT | ||||||